Key result
TAVI is a safe and effective alternative to surgical replacement for severe aortic stenosis, with comparable stroke rates but higher pacemaker requirements and uncertain long-term durability.
Why the study?
Does transcatheter aortic valve implantation improve clinical outcomes compared to surgical aortic valve replacement in patients with severe aortic stenosis?
Does transcatheter aortic valve implantation improve clinical outcomes compared to surgical aortic valve replacement in patients with severe aortic stenosis?
While TAVR is comparable to SAVR in higher-risk patients, specific device-related complications and durability concerns must be addressed before widespread adoption in lower-risk populations.
Answers are grounded in this paper and cite their sources.
TAVR approval for intermediate-risk severe AS warrants cautious adoption; leaves open durability and long-term outcome questions.
Transcatheter aortic valve implantation (TAVI) or replacement (TAVR) was recently approved by the FDA for intermediate risk patients with severe aortic stenosis (AS). This technique was already worldwide adopted for inoperable and high-risk patients. Improved device technology, imaging analysis and operator expertise has reduced the initial worrisome higher complications rate associated with TAVR, making it comparable to surgical aortic valve replacement (SAVR). However, many answers need to be addressed before adoption in lower risk patients. This paper highlights the pros and cons of TAVI based mostly on randomized clinical trials involving the two device platforms approved in the United States. We focused our analysis on metrics that will play a key role in expanding TAVR indication in healthier individuals. We review the significance and gave a perspective on paravalvular leak (PVL), valve performance, valve durability, leaflet thrombosis, stroke and pacemaker requirement.
No takes yet. Share an insight, caveat, or question.
Terre et al. (2017) conducted a review in Severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated. TAVI is a safe and effective alternative to surgical replacement for severe aortic stenosis, with comparable stroke rates but higher pacemaker requirements and uncertain long-term durability.
Synapse has enriched 10 related papers. Consider them for comparative context: